117 related articles for article (PubMed ID: 31653903)
1. C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4.
Suzuki K; Ui T; Nagano A; Hino A; Arano Y
Sci Rep; 2019 Oct; 9(1):15284. PubMed ID: 31653903
[TBL] [Abstract][Full Text] [Related]
2. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
3. High-Contrast CXCR4-Targeted
Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
[TBL] [Abstract][Full Text] [Related]
4. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
6. Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors.
Trotta AM; Aurilio M; D'Alterio C; Ieranò C; Di Martino D; Barbieri A; Luciano A; Gaballo P; Santagata S; Portella L; Tomassi S; Marinelli L; Sementa D; Novellino E; Lastoria S; Scala S; Schottelius M; Di Maro S
J Med Chem; 2021 Mar; 64(6):3449-3461. PubMed ID: 33660512
[TBL] [Abstract][Full Text] [Related]
7. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.
Gourni E; Demmer O; Schottelius M; D'Alessandria C; Schulz S; Dijkgraaf I; Schumacher U; Schwaiger M; Kessler H; Wester HJ
J Nucl Med; 2011 Nov; 52(11):1803-10. PubMed ID: 22045709
[TBL] [Abstract][Full Text] [Related]
8. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
9. A radiogallium-DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging.
Sano K; Masuda R; Hisada H; Oishi S; Shimokawa K; Ono M; Fujii N; Saji H; Mukai T
Bioorg Med Chem Lett; 2014 Mar; 24(5):1386-8. PubMed ID: 24491461
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.
Yang T; Shi D; Lin Q; Shen H; Tan H; Liu Y; Shi H; Cheng D
Mol Pharm; 2024 May; 21(5):2415-2424. PubMed ID: 38606663
[TBL] [Abstract][Full Text] [Related]
11. AMD3100: A Versatile Platform for CXCR4 Targeting (68)Ga-Based Radiopharmaceuticals.
Poty S; Gourni E; Désogère P; Boschetti F; Goze C; Maecke HR; Denat F
Bioconjug Chem; 2016 Mar; 27(3):752-61. PubMed ID: 26886512
[TBL] [Abstract][Full Text] [Related]
12. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
Cho BS; Zeng Z; Mu H; Wang Z; Konoplev S; McQueen T; Protopopova M; Cortes J; Marszalek JR; Peng SB; Ma W; Davis RE; Thornton DE; Andreeff M; Konopleva M
Blood; 2015 Jul; 126(2):222-32. PubMed ID: 26031918
[TBL] [Abstract][Full Text] [Related]
13. In vivo validation of
Renard I; Domarkas J; Poty S; Burke BP; Roberts DP; Goze C; Denat F; Cawthorne CJ; Archibald SJ
Nucl Med Biol; 2023; 120-121():108335. PubMed ID: 37068392
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor - Directed imaging and therapy.
Buck AK; Stolzenburg A; Hänscheid H; Schirbel A; Lückerath K; Schottelius M; Wester HJ; Lapa C
Methods; 2017 Nov; 130():63-71. PubMed ID: 28916148
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4.
Demmer O; Dijkgraaf I; Schumacher U; Marinelli L; Cosconati S; Gourni E; Wester HJ; Kessler H
J Med Chem; 2011 Nov; 54(21):7648-62. PubMed ID: 21905730
[TBL] [Abstract][Full Text] [Related]
16. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
[TBL] [Abstract][Full Text] [Related]
17. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.
Wester HJ; Keller U; Schottelius M; Beer A; Philipp-Abbrederis K; Hoffmann F; Šimeček J; Gerngross C; Lassmann M; Herrmann K; Pellegata N; Rudelius M; Kessler H; Schwaiger M
Theranostics; 2015; 5(6):618-30. PubMed ID: 25825601
[TBL] [Abstract][Full Text] [Related]
18. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
19. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.
Jacobson O; Weiss ID; Szajek L; Farber JM; Kiesewetter DO
Bioorg Med Chem; 2009 Feb; 17(4):1486-93. PubMed ID: 19188071
[TBL] [Abstract][Full Text] [Related]
20. [
Schottelius M; Osl T; Poschenrieder A; Hoffmann F; Beykan S; Hänscheid H; Schirbel A; Buck AK; Kropf S; Schwaiger M; Keller U; Lassmann M; Wester HJ
Theranostics; 2017; 7(9):2350-2362. PubMed ID: 28744319
[No Abstract] [Full Text] [Related]
[Next] [New Search]